Chinese biotechnology company Sophonix has recently completed a RMB100 million (US$14.14 million) series B funding round led by Zero2IPO Asset Management. Delian Capital, Anlong Fund, GoldTech Capital and existing investor ETP Fund also participated. Established in July 2017, Sophonix focuses on the development, production and sales of in vitro diagnostic instruments and reagents, providing accurate […] Zero2IPO Leads $14M Series B Round In Chinese Biotech Firm Sophonix comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.